| |
| |
|
| Insider
Information: |
Graham Peter J |
| Relationship: |
Officer |
| City: |
Lake Success |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
272,778 |
|
|
Indirect Shares
|
66,227 |
|
|
| Direct
Value |
$1,227,140 |
|
|
|
Indirect Value
|
$384,779 |
|
|
| Total
Shares |
339,005 |
|
|
| Total
Value |
$1,611,919 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
E-Z-EM Inc |
EZEM |
SVP - Chief Legal Offi... |
2008-04-01 |
0 |
2008-04-01 |
0 |
Premium* |
|
|
Angiodynamics Inc |
ANGO |
Director |
2006-10-25 |
27,778 |
2006-10-25 |
66,227 |
Premium* |
|
|
Delcath Systems Inc |
DCTH |
EVP; General Counsel |
2012-02-28 |
15,000 |
2011-03-10 |
0 |
Premium* |
|
|
Antares Pharma Inc |
ATRS |
See Remarks |
2022-05-24 |
0 |
2016-03-21 |
0 |
Premium* |
|
|
ADC Therapeutics Sa |
ADCT |
Officer |
2024-01-02 |
230,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
51 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADCT |
ADC Therapeutics Sa |
Chief Legal OfficerOfficer |
• – – |
2024-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
230,000 |
|
% |
|
| ANGO |
Angiodynamics Inc |
officerTitle |
– • – |
2006-01-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
66,227 |
|
- |
|
| ANGO |
Angiodynamics Inc |
officerTitle |
– • – |
2006-01-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,239 |
|
- |
|
| ANGO |
Angiodynamics Inc |
Director |
– • – |
2006-10-25 |
4 |
OE |
$2.57 |
$3,952 |
D/D |
1,539 |
27,778 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
SVP General Counsel, Secretary |
• – – |
2016-03-21 |
4 |
B |
$0.77 |
$15,400 |
D/D |
20,000 |
20,000 |
2.74 |
- |
|
| ATRS |
Antares Pharma Inc |
SVP General Counsel, Secretary |
• – – |
2016-06-02 |
4 |
A |
$1.12 |
$135,576 |
D/D |
121,050 |
141,050 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
SVP General Counsel, Secretary |
• – – |
2017-06-02 |
4 |
D |
$2.57 |
$42,747 |
D/D |
(16,633) |
124,417 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
SVP General Counsel, Secretary |
• – – |
2017-06-07 |
4 |
A |
$2.66 |
$269,814 |
D/D |
101,434 |
225,851 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2018-06-02 |
4 |
D |
$2.69 |
$41,485 |
D/D |
(15,422) |
210,429 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2018-06-07 |
4 |
D |
$2.70 |
$34,892 |
D/D |
(12,923) |
197,506 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2018-06-08 |
4 |
A |
$2.70 |
$247,501 |
D/D |
91,667 |
289,173 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2019-02-20 |
4 |
D |
$3.20 |
$103,635 |
D/D |
(32,386) |
341,522 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2019-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
84,735 |
373,908 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2019-06-02 |
4 |
D |
$2.79 |
$43,025 |
D/D |
(15,421) |
326,101 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2019-06-07 |
4 |
D |
$2.81 |
$36,311 |
D/D |
(12,922) |
313,179 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2019-06-08 |
4 |
D |
$2.81 |
$32,815 |
D/D |
(11,678) |
301,501 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2019-06-13 |
4 |
A |
$2.92 |
$247,499 |
D/D |
84,760 |
386,261 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2020-02-19 |
4 |
D |
$3.53 |
$105,713 |
D/D |
(29,947) |
419,548 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2020-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
63,234 |
449,495 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2020-06-07 |
4 |
D |
$3.12 |
$56,141 |
D/D |
(17,994) |
401,554 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2020-06-08 |
4 |
D |
$3.13 |
$50,897 |
D/D |
(16,261) |
385,293 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2020-06-11 |
4 |
A |
$2.73 |
$360,000 |
D/D |
131,868 |
517,161 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2020-06-13 |
4 |
D |
$2.78 |
$41,800 |
D/D |
(15,036) |
502,125 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2021-02-17 |
4 |
D |
$4.73 |
$199,005 |
D/D |
(42,073) |
540,417 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
EVP General Counsel, Secretary |
• – – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
80,365 |
582,490 |
0 |
- |
|
51 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
